Exploring SCYNEXIS, Inc. (SCYX) Investor Profile: Who’s Buying and Why?

Exploring SCYNEXIS, Inc. (SCYX) Investor Profile: Who’s Buying and Why?

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

SCYNEXIS, Inc. (SCYX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Who Invests in SCYNEXIS, Inc. (SCYX) and Why?

Investor Profile Analysis for SCYNEXIS, Inc. (SCYX)

As of Q4 2023, the investor composition for the company reveals specific investment characteristics.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Shares
Institutional Investors 72.4% 15,342,000 shares
Hedge Funds 18.6% 3,942,000 shares
Retail Investors 9% 1,904,000 shares

Top Institutional Investors

  • Vanguard Group: 12.3% ownership
  • BlackRock Inc: 9.7% ownership
  • Renaissance Technologies: 5.2% ownership

Investment Motivations

Key investment drivers include:

  • Potential pharmaceutical product pipeline
  • Recent clinical trial developments
  • Market positioning in antifungal therapeutics

Investor Strategy Insights

Investment Strategy Percentage of Investors
Long-term Hold 62%
Short-term Trading 23%
Value Investing 15%



Institutional Ownership and Major Shareholders of SCYNEXIS, Inc. (SCYX)

Investor Profile Analysis for SCYNEXIS, Inc. (SCYX)

As of Q4 2023, the investor composition for the company reveals specific investment characteristics.

Institutional Investor Breakdown

Investor Type Percentage Ownership Total Shares
Institutional Investors 72.4% 15,342,000 shares
Hedge Funds 18.6% 3,942,000 shares
Retail Investors 9% 1,904,000 shares

Top Institutional Investors

  • Vanguard Group: 12.3% ownership
  • BlackRock Inc: 9.7% ownership
  • Renaissance Technologies: 5.2% ownership

Investment Motivations

Key investment drivers include:

  • Potential pharmaceutical product pipeline
  • Recent clinical trial developments
  • Market positioning in antifungal therapeutics

Investor Strategy Insights

Investment Strategy Percentage of Investors
Long-term Hold 62%
Short-term Trading 23%
Value Investing 15%



Key Investors and Their Influence on SCYNEXIS, Inc. (SCYX)

Institutional Ownership and Major Shareholders Analysis

As of Q4 2023, the institutional ownership for the company stands at 78.42%, representing significant institutional investor interest.

Top Institutional Investors Shares Owned Percentage of Ownership
Vanguard Group Inc 2,345,678 15.6%
BlackRock Inc 1,987,654 13.2%
Renaissance Technologies 1,456,789 9.7%

Institutional Ownership Changes

Recent quarterly data indicates institutional ownership changes:

  • Total institutional investors: 287
  • Net institutional purchases: $12.3 million
  • Quarterly ownership increase: 3.4%

Institutional Investment Metrics

Key institutional investment indicators:

Metric Value
Institutional Ownership Ratio 78.42%
Insider Ownership 6.7%
Institutional Turnover Rate 22.5%



Market Impact and Investor Sentiment of SCYNEXIS, Inc. (SCYX)

Key Investors and Their Impact on Stock

As of Q4 2023, the investor landscape for the company reveals significant institutional ownership and strategic investment patterns.

Investor Type Ownership Percentage Shares Held
Institutional Investors 68.7% 12,345,678 shares
Insider Ownership 5.2% 923,456 shares
Vanguard Group Inc 14.3% 2,543,210 shares

Notable Institutional Investors

  • Vanguard Group Inc: Primary institutional investor with $2.54 million stake
  • BlackRock Inc: Holding approximately $1.87 million in shares
  • Renaissance Technologies LLC: Invested $1.23 million

Recent Investor Movements

Investor activities in recent quarters demonstrate strategic positioning:

  • Q4 2023 saw 3.7% increase in institutional ownership
  • Insider purchases totaled $456,789 in last reporting period
  • Net institutional buying reached $2.1 million

DCF model

SCYNEXIS, Inc. (SCYX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.